Earning Analysis
Welcome to our in-depth analysis of ADMA Biologics Inc(ADMA) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of ADMA Biologics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-05 | After Hours | 0.16 | 0.16 | - | 130.53M | 134.22M | +2.83 | -8.72 | +4.29 |
| FY2025Q2 | 2025-08-06 | After Hours | 0.14 | 0.15 | +7.14 | 121.77M | 121.98M | +0.18 | -9.65 | -9.60 |
| FY2025Q1 | 2025-05-07 | After Hours | 0.16 | 0.14 | -12.50 | 118.65M | 114.80M | -3.24 | -10.21 | -15.80 |
| FY2024Q4 | 2025-03-03 | After Hours | 0.15 | 0.14 | -6.67 | 112.80M | 117.55M | +4.21 | +7.45 | +4.93 |
| FY2024Q2 | 2024-08-08 | After Hours | 0.08 | 0.13 | +62.50 | 86.41M | 107.19M | +24.05 | +30.93 | +44.30 |
| FY2024Q1 | 2024-05-09 | - | 0.05 | 0.08 | +60.00 | 77.28M | 81.88M | +5.95 | +1.02 | +32.65 |
| FY2023Q4 | 2024-02-28 | - | 0.02 | 0.04 | +100.00 | 72.97M | 73.90M | +1.28 | -2.54 | +5.07 |
| FY2023Q3 | 2023-11-08 | - | -0.01 | 0.01 | +200.00 | 62.13M | 67.27M | +8.29 | -1.90 | +4.88 |
| - | 2023-05-10 | - | -0.05 | -0.03 | +40.00 | - | - | - | +2.88 | +17.58 |
| - | 2023-03-23 | - | -0.07 | -0.06 | +14.29 | - | - | - | +3.32 | +8.64 |
ADMA Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, ADMA Biologics Inc reported performance for FY2025Q3, announced on 2025-11-05. The company achieved an EPS of 0.16, compared to analyst estimates of 0.16 by 0.00% . Revenue for the quarter reached 134.22M compared to expectations of 130.53M by 2.83% .
The stock price reacted with a -8.72% one-day change and a 4.29% five-day change following the earnings release. These movements reflect market reaction in ADMA Biologics Inc growth trajectory and strategic initiatives.
ADMA Earnings Forecast
Looking ahead, ADMA Biologics Inc(ADMA) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 139.83M and an EPS of 0.19.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.91%, while EPS estimates have been Revise Upward by 3.84%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 1.5% . These revisions correlate with a 19.21% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ADMA Biologics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between ADMA's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+0.91%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+3.84%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+1.5%
In Past 3 Month
Stock Price
Go Up
+19.21%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:510.87M
--
EPS Estimate-Annual FY 2025:0.59
—
Stock Price20.11
ADMA Revenue and EPS Performance: A Historical Perspective
ADMA Biologics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-05,After Hours):
EPS: 0.16 (Actual) vs.0.16 (Estimate) (0.00%)
Revenue: 134.22M (Actual) vs. 130.53M (Estimate) (2.83%)
Price Reaction: -8.72%(1-Day), 4.29%(5-Day)
FY2025Q2 (2025-08-06,After Hours):
EPS: 0.15 (Actual) vs.0.14 (Estimate) (7.14%)
Revenue: 121.98M (Actual) vs. 121.77M (Estimate) (0.18%)
Price Reaction: -9.65%(1-Day), -9.60%(5-Day)
FY2025Q1 (2025-05-07,After Hours):
EPS: 0.14 (Actual) vs.0.16 (Estimate) (-12.50%)
Revenue: 114.80M (Actual) vs. 118.65M (Estimate) (-3.24%)
Price Reaction: -10.21%(1-Day), -15.80%(5-Day)
Earnings Reaction
The chart below shows how ADMA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ADMA sees a -3.43% change in stock price 10 days leading up to the earnings, and a +12.72% change 10 days following the report. On the earnings day itself, the stock moves by +1.08%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -8.72% on the day following the earnings release and then changed by 3.77% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
ADMA Biologics Inc (ADMA) Q3 2025 Earnings Call Summary
Positive
2025-11-05
The earnings call summary presents strong financial metrics, including a 10% QoQ revenue increase and significant gross margin expansion. The Q&A reveals optimism about ASCENIV's market potential and raised 2026 guidance, despite some management ambiguity. No negative trends were identified. Given the market cap, a positive stock price movement (2% to 8%) is anticipated due to strong financial performance, optimistic guidance, and strategic growth initiatives.
ADMA Biologics Inc (ADMA) Q2 2025 Earnings Call Summary
Positive
2025-08-06
The earnings call shows strong financial performance with a 14% revenue increase, improved gross margins, and positive cash flow. The company has raised its revenue and EBITDA guidance for 2025 and 2026, indicating optimism. The stock repurchase program is value-accretive. The Q&A highlights strong demand and no margin headwinds, though some uncertainty exists regarding HEOR data. Overall, given the market cap, the positive financial results, and strategic initiatives like yield enhancement, the stock is likely to see a positive reaction in the short term, within the 2% to 8% range.
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Summary
Positive
2025-05-07
The earnings call highlights strong financial performance, including 40% revenue growth and improved margins. The stock repurchase program and reduced debt costs further boost investor confidence. While some management responses lacked clarity, the overall sentiment is positive due to the optimistic guidance, successful FDA approval, and robust supply chain improvements. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Summary
Positive
2025-03-04
Despite missing EPS expectations, ADMA Biologics showed strong financial performance with significant revenue and income growth. Optimistic guidance and potential billion-dollar opportunities in ASCENIV and SG-001 further bolster sentiment. The Q&A section revealed positive demand trends and operational efficiency improvements, although some management responses lacked clarity. Given the company's small-cap status and strong growth trajectory, the stock is likely to experience a positive price movement over the next two weeks.
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Summary
Positive
2025-03-03
The company demonstrated exceptional financial performance with a significant increase in revenue and net income. The optimistic guidance for 2025 and 2026, especially regarding ASCENIV and SG-001, coupled with strong gross margins, suggests a promising outlook. The Q&A section indicated robust demand for ASCENIV, though some details were vague. Given the company's market cap of approximately $2.5 billion, this strong financial and strategic position, alongside positive market sentiment, is likely to result in a strong positive stock price movement over the next two weeks.
ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Summary
Positive
2024-11-08
ADMA's earnings call reveals strong financial performance with significant revenue growth and improved margins, alongside optimistic guidance for 2024 and 2025. Despite competitive pressures and supply chain challenges, the company's strategic initiatives like the VIP donor program and anticipated ASCENIV pediatric label expansion are promising. The Q&A section highlighted some concerns about plasma supply but overall sentiment remains positive, supported by increased net income and EBITDA guidance. Given the mid-cap status, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
People Also Watch
FAQ
What were the key highlights of ADMA’s latest earnings report for FY2025Q3?
How did ADMA’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for ADMA for 2025/Q4?
How does ADMA’s stock price correlate with earnings forecast revisions?
What should investors expect from ADMA’s next earnings report?